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Genome wide analysis of gene dosage in 24,092 individuals estimates that 10,000 genes 1 
modulate cognitive ability 2 
 3 
Single sentence summary: CNVs’ effect-sizes on intelligence are predicted using measures of 4 
intolerance to haploinsufficiency and are distributed across half of the coding genes. 5 
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ABSTRACT 60 
Genomic Copy Number Variants (CNVs) are routinely identified and reported back to patients 61 
with neuropsychiatric disorders, but their quantitative effects on essential traits such as cognitive 62 
ability are poorly documented. We have recently shown that the effect-size of deletions on 63 
cognitive ability can be statistically predicted using measures of intolerance to 64 
haploinsufficiency. However, the effect-sizes of duplications remain unknown. It is also 65 
unknown if the effect of multigenic CNVs are driven by a few genes intolerant to 66 
haploinsufficiency or distributed across tolerant genes as well. 67 
Here, we identified all CNVs >50 kilobases in 24,092 individuals from unselected and autism 68 
cohorts with assessments of general intelligence. Statistical models used measures of intolerance 69 
to haploinsufficiency of genes included in CNVs to predict their effect-size on intelligence. 70 
Intolerant genes decrease general intelligence by 0.8 and 2.6 points of IQ when duplicated or 71 
deleted, respectively. Effect-sizes showed no heterogeneity across cohorts. Validation analyses 72 
demonstrated that models could predict CNV effect-sizes with 78% accuracy. Data on the 73 
inheritance of 27,766 CNVs showed that deletions and duplications with the same effect-size on 74 
intelligence occur de novo at the same frequency. 75 
We estimated that around 10,000 intolerant and tolerant genes negatively affect intelligence when 76 
deleted, and less than 2% have large effect-sizes. Genes encompassed in CNVs were not enriched 77 
in any GOterms but gene regulation and brain expression were GOterms overrepresented in the 78 
intolerant subgroup. Such pervasive effects on cognition may be related to emergent properties of 79 
the genome not restricted to a limited number of biological pathways. 80 




Copy Number Variants (CNVs) are deletions or duplications larger than 1000 base pairs. The 84 
contribution of CNVs to the etiology of intellectual disability (ID)[1–3], autism[4–6] and 85 
schizophrenia[6–8] is well established. The interpretation of CNVs in research and medical 86 
diagnostics remains essentially binary: benign or pathogenic (contributing to mental illness)[9]. 87 
The routine implementation of Chromosomal Micro-Arrays (CMAs) as a first-tier diagnostic test 88 
identifies “pathogenic” CNVs in 10 to 15 % of children with neurodevelopmental disorders 89 
(NDD)[10]. A binary interpretation is however of limited use because patients present a broad 90 
spectrum of cognitive symptoms ranging from severe ID to learning disabilities. The quantitative 91 
effects of CNVs are poorly documented even for important traits such as general intelligence. It 92 
may be available for the most frequently recurrent CNVs but data is often collected in patients 93 
ascertained in the clinic with a bias towards severely affected individuals, leading to potentially 94 
gross overestimation of effect size. Only two studies have been conducted in unselected 95 
populations [11, 12] showing reduced performance on cognitive test for 24 recurrent CNVs. 96 
However, recurrent CNVs only represent a very small fraction of the total amount of ultra-rare 97 
CNVs identified in the neurodevelopmental disorder clinic as well as in the general population.  98 
 99 
Intelligence is a major trait assessed in the developmental pediatric and psychiatric clinic. There 100 
is a significant genetic correlation between intelligence and psychiatric disorders and cognitive 101 
impairments represent a major referral criterion to the NDD clinic. The heritability of general 102 
intelligence is estimated at around 50 to 80% [13]. The heritability of variants in linkage 103 
disequilibrium with common SNPs is estimated to be around 22.7%, with variants in poor linkage 104 
disequilibrium with SNPs, including rare CNVs, explaining 31.3% of the phenotypic variation in 105 
intelligence[14]. Two recent GWAS, have identified over 200 loci associated with intelligence 106 
and education[15, 16] , potentially implicating 1000 genes. The latter were largely non-107 
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overlapping with genes previously linked to ID[15]. Contrary to SNPs, there is no ambiguity in 108 
the molecular interpretation of a fully deleted or duplicated gene, which invariably decreases or 109 
increases transcription respectively. Therefore, CNVs represent a powerful tool to map the effect-110 
sizes of genes (altered by gene dosage) on human traits. 111 
We have previously proposed a framework to estimate and predict the effect-size on intelligence 112 
of CNVs. We showed that linear models[17] using the sum of the “probability of being loss-of-113 
function intolerant” (pLI) scores[18] of all genes included in a deletion can predict their effect-114 
size on intelligence quotient (IQ) with 75% accuracy. Our initial study was underpowered to 115 
measure the effect-size of duplications. It is also unknown if only a limited number of intolerant 116 
genes or a large proportion of genes within CNVs are driving effects on cognitive abilities. More 117 
broadly, the number of genes modulating general intelligence remains unknown. The pLI used in 118 
our earlier model, ranges from 0 to 1 but has a bimodal distribution and is essentially a 119 
categorical variable classifying genes as intolerant (>0.9) or tolerant (≤0.9) to protein-loss-of-120 
function (pLoF) [18]. Continuous measures such as the LOEUF[19] (Loss-of-function 121 
Observed/Expected Upper bound Fraction) were recently introduced to reflect the full spectrum 122 
of intolerance to pLoF. LOEUF range from 0 to 2, and values below 0.35 are suggestive of 123 
intolerance. 124 
Our present aims were 1) to test the robustness of effect-size estimates for CNVs across 125 
unselected and NDD populations, 2) to establish the effect-size on general intelligence of 126 
genomic duplications, 3) to investigate the quantitative relationship between effect-size on 127 
general intelligence and the frequency of de novo events, and 4) to estimate individual effect-128 
sizes for all protein-coding genes that are intolerant as well as tolerant to pLoF. 129 
We identified CNVs in 24,092 individuals from five general populations, two autism cohorts and 130 
one neurodevelopmental cohort. Measures of intolerance to pLoF were used as variables to 131 
estimate the effect of CNVs and individual genes on general intelligence. Validation procedures 132 
 5 
using cognitive data on CNVs from 47 published reports and the UKBB demonstrated a near 133 
80% accuracy of model estimated. We implemented an online tool to help clinicians and 134 
researchers estimate the effect-size of any CNVs on general intelligence.  135 
 6 
Materials and Methods 136 
1. Cohorts  137 
We included five cohorts from the general population, two autism cohorts and one familial cohort 138 
with at least one CNV-carrier child recruited for a neurodevelopmental disorder (Table1). Studies 139 
for each cohort were reviewed by local institutional review boards. Parents/guardians and adult 140 
participants gave written informed consent and minors gave assent. 141 
2. Measures of general intelligence 142 
General intelligence was assessed using the neurocognitive tests detailed in table 1. Measures of 143 
non-verbal intelligence quotient (NVIQ) were available in five cohorts and general intelligence 144 
factor (g-factor)[20] was computed in four cohorts, based on cognitive tests, primarily assessing 145 
fluid non-verbal reasoning (Table1, Supplementary Fig. 1). Intelligence measures were 146 
normalized using z-score transformations to render them comparable. The concordance between 147 
z-scored NVIQ and g-factor available for three cohorts ranged from 60 to 77% (Supplementary 148 
Table 1). 149 
3. Genetic information 150 
CNV calling and filtering 151 
For all SNP array data, we called CNVs with PennCNV and QuantiSNP using previously 152 
published methods [17]. For the MSSNG dataset[21], we used CNVs called on whole genome 153 
sequencing by Trost et al. [22].  154 
CNV filtering steps were previously published (Supplemental material). For the mega-analysis, 155 
we applied an additional filtering criterion, selecting CNVs encompassing at least 10 probes for 156 
all array technologies used across all cohorts.  157 
The Sainte-Justine CNV-family cohort included participants on the basis of one pathogenic CNV 158 
identified in the diagnostic cytogenetic laboratory using an Agilent 180K array. 159 
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Annotation of CNVs 160 
We annotated the CNVs using Gencode V19 (hg19) with ENSEMBL 161 
(https://grch37.ensembl.org/index.html). Genes with all transcripts fully encompassed in CNVs 162 
were annotated using 12 variables present in previous article[17]. Non-coding regions were 163 
annotated with the number of expression quantitative trait loci (eQTLs) regulating genes 164 
expressed in the brain[23]. CNV scores were derived by summing all scores of genes within 165 
CNVs.[17]. Also, we used a list of 256 ID-genes[2, 24], previously identified with an excess of 166 
de-novo mutations in NDD cohorts. 167 
 168 
4. Statistical analyses 169 
Modelling the effect of CNVs on intelligence 170 
General intelligence was adjusted within each cohort for age and sex when required (𝑍𝑍𝑎𝑎𝑎𝑎𝑎𝑎 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 .; 171 
see supplemental material and Supplementary Fig. 2 and 3). To estimate the effect of CNVs on 172 
general intelligence, we fit the model developed by Huguet at al. [17] where the sum of pLI (or 173 
any of the 10 other scores) for all genes encompassed in deletions or duplications, respectively, is 174 
the variable used to predict the adjusted Z-score of general intelligence:  175 
Model for deletion (ℳ1𝐷𝐷𝐷𝐷𝐷𝐷): 𝑍𝑍𝑎𝑎𝑎𝑎𝑎𝑎 𝑖𝑖𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼.  ~ 𝛽𝛽0,𝐷𝐷𝐷𝐷𝐷𝐷 + 𝛽𝛽1,𝐷𝐷𝐷𝐷𝐷𝐷  × ∑ 𝑝𝑝𝑝𝑝𝑝𝑝𝑔𝑔𝐼𝐼𝐼𝐼𝐼𝐼  176 
where 𝛽𝛽0,𝐷𝐷𝐷𝐷𝐷𝐷 , 𝛽𝛽1,𝐷𝐷𝐷𝐷𝐷𝐷  are the regression coefficients. The same model was applied to duplications. 177 
First, models ℳ1𝐷𝐷𝐷𝐷𝐷𝐷  and ℳ1𝐷𝐷𝐷𝐷𝐷𝐷  were fitted independently and adjusted for each cohort and 178 
results were used in the meta-analyses. Second, in the mega-analysis, ℳ1𝐷𝐷𝐷𝐷𝐷𝐷  and ℳ1𝐷𝐷𝐷𝐷𝐷𝐷  were 179 
fitted after pooling all samples and adjusting on the type of cognitive measure and cohort. 180 
To take into account ID-genes that have a greater impact on intelligence, we used a model 181 
including 4 predictive variables (ℳ2):  182 
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𝑍𝑍𝑎𝑎𝑎𝑎𝑎𝑎 𝑖𝑖𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼. ~ 𝛽𝛽0 +  𝛽𝛽1 × �
1
𝑝𝑝𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿
𝐼𝐼𝐷𝐷 𝑔𝑔𝐼𝐼𝐼𝐼𝐼𝐼 𝑖𝑖𝐼𝐼 𝑎𝑎𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑖𝑖𝑑𝑑𝐼𝐼
+ 𝛽𝛽2 × �
1
𝑝𝑝𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿
𝐼𝐼𝐷𝐷 𝑔𝑔𝐼𝐼𝐼𝐼𝐼𝐼 𝑖𝑖𝐼𝐼 𝑎𝑎𝑑𝑑𝑑𝑑𝐼𝐼𝑖𝑖𝑑𝑑𝑎𝑎𝐼𝐼𝑖𝑖𝑑𝑑𝐼𝐼




𝐼𝐼𝑑𝑑𝐼𝐼−𝐼𝐼𝐷𝐷 𝑔𝑔𝐼𝐼𝐼𝐼𝐼𝐼 𝑖𝑖𝐼𝐼 𝑎𝑎𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑖𝑖𝑑𝑑𝐼𝐼
+ 𝛽𝛽4 × �
1
𝑝𝑝𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿
𝐼𝐼𝑑𝑑𝐼𝐼−𝐼𝐼𝐷𝐷 𝑔𝑔𝐼𝐼𝐼𝐼𝐼𝐼 𝑖𝑖𝐼𝐼 𝑎𝑎𝑑𝑑𝑑𝑑𝐼𝐼𝑖𝑖𝑑𝑑𝑎𝑎𝐼𝐼𝑖𝑖𝑑𝑑𝐼𝐼
 184 
where 𝛽𝛽0, 𝛽𝛽1, 𝛽𝛽2, 𝛽𝛽3 and 𝛽𝛽4 are the regression coefficients. 185 
The variance explained by deletions and duplications (measured by pLI) was computed using 186 
partial R2 in the full dataset as well as the subgroup (n=14,874) of unrelated individuals. 187 
Sensitivity analyses 188 
We tested non-linearity of the effect of haploinsufficiency scores on general intelligence by using 189 
polynomial regression model and by exploring a smooth function of the effect of 190 
haploinsufficiency scores using a Gaussian kernel regression method (https://cran.r-191 
project.org/web/packages/KSPM/index.html) flexible enough to account for various types of 192 
effects (Supplementary material). 193 
Model Validation 194 
To validate our models, we computed the concordance between model predictions and loss of IQ 195 
measured for 47 recurrent CNVs obtained in previous publications (supplementary material). The 196 
concordance was computed using the intraclass coefficient correlation of type (3,1) (ICC(3,1)) 197 
[25]. 198 
Modelling the probability to be de novo 199 
We performed logistic regressions to estimate the probability of a CNV being de novo (𝑃𝑃𝑎𝑎𝐼𝐼 𝐼𝐼𝑑𝑑𝑛𝑛𝑑𝑑) 200 
as a function of the haploinsufficiency scores: 201 
 202 
Model for deletions (ℳ3𝐷𝐷𝐷𝐷𝐷𝐷):  203 
logit(𝑃𝑃𝑎𝑎𝐼𝐼 𝐼𝐼𝑑𝑑𝑛𝑛𝑑𝑑) ~ 𝛽𝛽0,𝐷𝐷𝐷𝐷𝐷𝐷 +  𝛽𝛽1,𝐷𝐷𝐷𝐷𝐷𝐷 × 𝑍𝑍𝑎𝑎𝑎𝑎𝑎𝑎 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 .𝑖𝑖𝑒𝑒𝑖𝑖𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎 𝑏𝑏𝑏𝑏 ℳ2 𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑖𝑖.   204 
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where 𝛽𝛽0,𝐷𝐷𝐷𝐷𝐷𝐷 , 𝛽𝛽1,𝐷𝐷𝐷𝐷𝐷𝐷  are the regression coefficients. The same model was applied to duplications 205 
(ℳ3𝐷𝐷𝐷𝐷𝐷𝐷) 206 
For these analyses, we added two clinical populations (Decipher, decipher.sanger.ac.uk/) and the 207 
cytogenetic database of Sainte-Justine Hospital, where genetic data could be compared between 208 
the child and their parents, and applied the same filtering as for the previous CNV selection 209 
leading to a total of 26,437 CNVs. (Supplementary Table 2). The binary outcome variable was 210 
the type of transmission (1=de novo, 0=inherited). 211 
To validate these models, we computed the concordance between model estimates and percentage 212 
of de novo variants computed with Decipher for 27 recurrent CNVs. 213 
Estimating the effect-size of individual genes based on LOEUF values 214 
We used 4 categories of LOEUF values to estimate the effect-size of genes classified as highly 215 
intolerant (LOEUF <0.2, n=980), moderately intolerant (0.2≤LOEUF<0.35 n=1,762), tolerant 216 
(0.35≤LOEUF<1, n=7,442), and highly tolerant to haploinsufficiency (LOEUF≥1, n=8,267). For 217 
deletions, model 4 is as follow:  218 
 (ℳ4𝑎𝑎𝐼𝐼𝐼𝐼):  219 
Zadj intell. ~ 𝛽𝛽0 +  𝛽𝛽1 × �(ℎ𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑏𝑏 𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑒𝑒 𝑖𝑖 ) +  𝛽𝛽2 × �(𝑒𝑒𝑑𝑑𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑏𝑏 𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑒𝑒 𝑖𝑖 ) 220 
+ 𝛽𝛽3 × �(𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑒𝑒 𝑖𝑖 ) +  𝛽𝛽4 × �(ℎ𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑏𝑏 𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑒𝑒 𝑖𝑖 ) 221 
where 𝛽𝛽0,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼 , 𝛽𝛽1,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼 , 𝛽𝛽2,𝐶𝐶𝐶𝐶𝐶𝐶  𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼 , 𝛽𝛽3,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼  and 𝛽𝛽4,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼  are the regression 222 
coefficients. The same model was applied for duplications. 223 
To explore smaller categories of LOEUF values, we slid a window of size 0.15 LOEUF units, in 224 
increments of 0.05 units thereby creating 38 categories across the range of LOEUF values. We 225 
performed 38 linear models: 226 
(ℳ5𝑎𝑎𝐼𝐼𝐼𝐼 ):  227 
Zadj intell.  ~ 𝛽𝛽0,𝐶𝐶𝐶𝐶𝐶𝐶  𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼 +  𝛽𝛽1,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼  × �(genes 𝑖𝑖 inside the window) 228 
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+ 𝛽𝛽2,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼  ×  �(genes 𝑖𝑖 outside the window ) 229 
where 𝛽𝛽0,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼 , 𝛽𝛽1,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼  and 𝛽𝛽2,𝐶𝐶𝐶𝐶𝐶𝐶 𝐼𝐼𝑡𝑡𝑑𝑑𝐼𝐼  are the regression coefficients. 230 
The same models were performed for duplications. Estimates were corrected for multiple testing 231 
(38 tests) using FDR. 232 
GOterms Enrichment 233 
For the GOterms enrichment for the tolerant and intolerant genes with all a genome and CNVs 234 
between unselected, ASD and both populations, we used DAVID release 6.8[26] (https://david-235 
d.ncifcrf.gov). We kept the defaults parameters and save only the terms with Bonferroni 236 
corrected p-values <0.05. We then passed the list to REVIGO[27] (http://revigo.irb.hr/) to 237 
summarize and group the redundant GO. 238 
 239 
  240 
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RESULTS 241 
1)  Deletions and duplications have a 3:1 effect-size ratio on general intelligence 242 
We first sought to replicate our previous estimates for the effect-size of deletions on 243 
general intelligence computed using pLI [17]. We performed a meta-analysis on 20,151 244 
individuals from 5 unselected populations (Table 1, Supplementary Fig. 1) showing that the 245 
deletion of one point of pLI decreases NVIQ or g-factor by 0.18 z-score (95% CI: -0.23 to -0.14, 246 
equivalent to 2.7 points of NVIQ, Fig. 1a, Supplementary Table 3). For duplications, we 247 
performed a meta-analysis using the same unselected populations. It shows that duplicating one 248 
point of pLI decreases NVIQ or g-factor by 0.04 z-score (95% CI: -0.09 to -0.01), which is 249 
equivalent to 0.75 points of IQ. Of notes, our previous study [17] was unable to estimate effect-250 
sizes of duplications on general intelligence, likely due to sample size. There was no 251 
heterogeneity across cohorts. Sensitivity analyses showed that methods used for cognitive 252 
assessments did not influence these results (Fig. 1, Supplementary Table 4). 253 
 254 
2) The effect-size of CNVs on general intelligence is not influenced by ascertainment. 255 
Since genomic variants with large effects on general intelligence are thought to be removed 256 
from the general population as a result of negative selective pressure, this may have led to an 257 
underestimation of the effect-size of CNVs in unselected populations. To examine this 258 
possibility, we analyzed 3,941 individuals (Table 1, Supplementary Fig. 1) from two autism 259 
cohorts, which include individuals with ID and de novo CNVs. Effect-sizes of pLI on general 260 
intelligence were similar in males and females with autism, and the same than those observed in 261 
unselected populations for deletions and duplications (Supplementary table 5 and 6). We did not 262 
observe any heterogeneity across cohorts (Fig. 1, Supplementary Table 3). Finally, we asked if 263 
effect-sizes of pLI were the same in large CNVs rarely observed in the general population or in 264 
autism cohorts. We tested 226 CNV carriers and 325 intrafamilial controls from 132 families 265 
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ascertained in the clinic (Table 1). Effect-sizes of pLI on IQ were very similar with a decrease of 266 
0.147 z-score, 95% CI: -0.18 to -0.11 (P= 1.1×10-15) in deletions and 0.069 z-score, 95% CI: -0.1 267 
to -0.04 (P=8.7×10-6) in duplications (Supplementary Table 7).  268 
 269 
3) Mega-analysis suggests additive effects of constraint scores on general intelligence 270 
We pooled samples after adjusting for variables including cognitive test and cohorts to perform a 271 
mega-analysis of 24,092 individuals carrying 13,001 deletions and 15,856 duplications 272 
encompassing 36% of the coding genome (Fig. 1b, Supplementary Fig. 4a). The effect-size of 273 
pLI was unchanged, decreasing general intelligence by 0.175 z-score (SE=0.016, P=1.25×10-28) 274 
and 0.054 z-score (SE=0.009, P=1.90×10-9) for deletions and duplications, respectively 275 
(Supplementary Table 8). The partial R2 shows that deletions and duplications measured by pLI 276 
explain respectively 0.5% and 0.1% of the total variance of intelligence in the complete dataset; 277 
in line with the fact that large effect-size CNVs are rare in the general population. 278 
Among 11 variables, the 2 main constraint scores (pLI and 1/LOEUF) best explained (based on 279 
AIC) the variance of general intelligence (Supplementary Table 8). For the remainder of the 280 
study, we transitioned to using LOEUF because it is a continuous variable (the pLI is essentially 281 
binary) and is now recommended as the primary constraint score by gnomAD. Analyses using 282 
pLI are presented in supplemental results. 283 
There was no interaction between constraint scores and age or sex (Supplementary Table 5, 6, 9 284 
and 10). Non-linear models did not improve model fit (Supplementary Table 11 to 12), 285 
suggesting an additive effect of constraint scores. 286 
 287 
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4) The effect-size of 1/LOEUF on intelligence is the same in recurrent neuropsychiatric 288 
CNVs and non-recurrent CNVs 289 
We show that removing 608 individuals carrying any of the 121 recurrent CNV previously 290 
associated with neuropsychiatric conditions[17] does not influence the effect-size of 1/LOEUF 291 
on general intelligence (Supplementary Table 13). It has been posited that the deleteriousness of 292 
large psychiatric CNVs may be due to interactions between genes encompassed in CNVs. We 293 
therefore asked if the effect-size of 1/LOEUF is the same for CNVs encompassing small and 294 
large numbers of genes. We recomputed the linear model 6 times after incrementally excluding 295 
individuals with a total sum of 1/LOEUF ≥60, 40, 20, 10, 4 and 2.85 for deletions and 296 
duplications separately. Effect-sizes remain similar whether deletions encompass >10 or >60 297 
points of 1/LOEUF (Fig. 1d, Supplementary Fig. 4b). 298 
5) Gene dosage of 1% of coding genes shows extreme effect-size on general intelligence.  299 
Our ability to estimate large effect sizes is likely hampered by the explanatory variable 300 
(1/LOEUF) used in the model because there is only a 60-fold difference between the smallest and 301 
largest value. To improve model accuracy for large effect-size genes, we used a list of 256 ID-302 
genes[2, 24], previously identified with an excess of de novo mutations in NDD cohorts. We 303 
identified 126 CNVs encompassing at least one ID-gene (Fig. 2). 304 
We recomputed the model by integrating 4 explanatory variables: the sum of 1/LOEUF for ID 305 
and non-ID-genes encompassed in deletions and duplications. The effect-size on intelligence of 306 
1/LOEUF for ID-genes was 7 to 11-fold higher than the effect-size of non-ID genes which 307 
remained unchanged (Supplementary Table 14, 15 and Fig. 5). The mean effect of ID-genes 308 
intolerant to pLoF (LOEUF<0.35) was a decrease of 20 points of IQ for deletions and 9 points for 309 
duplications (Supplementary Table 15). 310 
 311 
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6) Model explains nearly 80% of the effect-size of CNVs.  312 
As a validation procedure, we compared model estimates to published observations for 47 313 
recurrent CNVs reported in clinical series and in the UKBB[11] (Supplementary Table 16 and 314 
17). When cognitive data was available from both clinical and the UKBB (n=13), we used the 315 
mean of both effect-sizes. Concordance between model estimates and previously published 316 
measures was 0.78 for all CNVs (95% CI, 0.66-0.86, P= 4.3×10-11, Fig. 3). Accuracy was similar 317 
for deletions (ICC=0.71 [0.5;0.84], P= 1.8×10-5) and duplications (ICC=0.85 [0.7;0.93], P= 3×10-318 
7) as well as for small and large CNVs including trisomy 21 (Fig. 3a and 3b, Supplementary Fig. 319 
6 and 7). 320 
 321 
7) CNVs with the same impact on intelligence have the same de novo frequency. 322 
Because measures of intolerance to haploinsufficiency explain equally well the effect-sizes of 323 
deletions and duplications on intelligence, we investigated the relationship between effects on 324 
intelligence and de novo frequency for deletions and duplications. We established inheritance for 325 
26,437 CNVs in 6 cohorts (Supplementary Table 2). There was a strong relationship between 326 
effects on general intelligence estimated by the model and the frequency of de novo observations 327 
for deletions (P=1.9×10-65) and duplications (P=4.6×10-24, Fig. 3c). 328 
Deletions and duplications with the same impact on general intelligence show similar de novo 329 
frequency CNVs (Fig. 3c).  330 
The concordance between the probability of occurring de novo estimated by the model (after 331 
removing recurrent CNVs) and de novo frequency reported in the DECIPHER database on 31 332 
recurrent CNVs was 0.81 ([0.67-0.9]; P=8.2×10-8) (Fig. 3d, Supplementary Table 18 and Fig. 8). 333 
 334 
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8) Estimating effect-sizes of individual genes using LOEUF 335 
Since we were underpowered to perform a gene-based GWAS, we first divided all genes in 4 336 
categories: highly intolerant genes (LOEUF<0.2; n=980), moderately intolerant genes 337 
(0.2≤LOEUF<0.35 n=1,762), tolerant genes (0.35≤LOEUF<1; n=7,442) and highly tolerant 338 
genes (LOEUF≥1; n=8,267). This dichotomization of LOEUF values also allowed to test whether 339 
the previous linear models were driven by subgroups of genes. The sum of genes in each category 340 
was used as four explanatory variables to explain general intelligence in the same linear model. 341 
For deletions, highly, moderately intolerant and tolerant genes showed negative effects on 342 
general intelligence (Fig. 4a, Supplementary Table 19). For duplications only moderately 343 
intolerant genes showed negative effects (Supplementary Fig. 9 and Table 19). 344 
We were underpowered to further subdivide these LOEUF categories, so we tested 38 345 
overlapping LOEUF categories in 38 linear models. Each model used 2 explanatory variables: 346 
number of genes within and outside the LOEUF category (size = 0.15 LOEUF). For 347 
haploinsufficiency, negative effects on general intelligence were observed for genes within 13 348 
categories across intolerant and tolerant LOEUF values. For duplications, only 2 categories had 349 
negative effects (Fig. 4a, Supplementary Fig.9 and Table 20). 350 
 351 
9) Most biological functions affect cognition. 352 
The 6,114 different genes encompassed in the CNVs of our dataset did not show any GOterm 353 
enrichment except for olfactory related terms (Supplementary Tables 21). We asked if intolerant 354 
(LOEUF<0.35) and tolerant genes (0.35<LOEUF<1), which negatively affect IQ in the analysis 355 
above were enriched in GOterms. All intolerant and tolerant genes genome-wide, were enriched 356 
in 365 and 30 GOterms respectively (Fig. 4b, Supplementary Tables 22, 23). The largest group of 357 
GOterms enriched in intolerant genes represented gene regulation (RNA polymerase II 358 
transcription factor activity, chromatin organization; Supplementary Fig. 10), cell death 359 
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regulation and neuronal function (dendrite and synapse). Among 23 tissues overrepresented in 360 
intolerant genes, adult brain and epithelium showed the strongest enrichment (Supplementary 361 
Table 22). Top enriched pathways included those in cancer, focal adhesion, Wnt signaling and 362 
MAPK (Supplementary Table 22). For tolerant genes, milder enrichments included translation 363 
(tRNA) and cytoskeletal structure. Among the 7 significant tissues adult brain showed the 364 
strongest enrichment (Fig. 4b, Supplementary Table 23 and Fig. 11). The 2,862 intolerant and 365 
tolerant genes encompassed in the CNVs of our dataset showed the same GOterm distribution 366 
observed above for the full intolerant and tolerant coding genome. Genes encompassed in CNVs 367 
were therefore represented well all molecular functions observed for each LOEUF group at the 368 




Deletions and duplications have effect-sizes on cognitive ability that are robust across cohorts, 372 
clinical diagnoses, and general intelligence assessments. The effect-size ratio on cognitive ability 373 
of deletions to duplications is 3:1. The linear sum of pLI or 1/LOEUF predicted the effect-size on 374 
intelligence of deletions and duplications with equal accuracy (78%). Using categories of LOEUF 375 
values, we provide the first estimates for the individual effect-sizes of protein-coding genes, 376 
suggesting that half of the coding genome affects intelligence. The 2,862 genes encompassed in 377 
CNVs of our dataset show the same GOterm distribution observed in the intolerant and tolerant 378 
coding genome. 379 
 380 
Model validation and ascertainment biases 381 
Models show 78% concordance with effect-size of CNVs on IQ from previous literature reports. 382 
Estimates are discordant for several CNVs, which may be due to either 1) unidentified large 383 
effect-size genes with unreliable LOEUF measures due to the small size of the protein coding 384 
region, and 2) ascertainment bias. However, biases from clinically referred individuals can be 385 
adjusted for using intrafamilial controls [28, 29]. This is confirmed by effect-sizes using the Ste 386 
Justine family genetic cohort. Also, our results suggest that the effect-size of pathogenic CNVs 387 
are underestimated in the UKBB[28] while those of small CNVs are largely overestimated in 388 
clinical series. The maximum effect size measured in UKBB was only 0.4 z-score including 389 
pathogenic CNVs such as 16p11.2, 2q11.2 deletions and 10q11.21-q11.23 deletion containing an 390 
ID-gene (WDFY4). On the other hand, the effect size of variants such as the 16p13.11 391 
duplications and 1q21.1 CNVs are likely overestimated in clinical series[30]. Therefore, 392 
statistical models using a variety of disease and unselected cohorts are likely to provide the most 393 
accurate estimates. Surprisingly, an autism diagnosis is not associated with a different impact of 394 
CNVs on cognitive ability. A recent study characterizes this finding showing that CNVs similarly 395 
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decrease IQ in autism and in unselected populations but are nevertheless more frequent in autism 396 
than in controls with same intelligence[31]. 397 
 398 
Individual effect-sizes of genes, and go their GOterm enrichments 399 
Our study is based on CNVs encompassing intolerant and tolerant genes with the same GOterm 400 
distribution observed in those LOEUF categories genome-wide. Only one percent of coding 401 
genes with the highest intolerance to pLoF has large effects on cognitive ability (20 and 9 IQ 402 
points for deletions and duplications of ID genes). The rest of the intolerant genes (15% of coding 403 
genes) have moderate to mild effect-sizes. The group of all intolerant genes is enriched in many 404 
GOterms including brain expression and gene regulation as previously reported for this group[2, 405 
32]. Genes considered tolerant to pLoF (0.35<LOEUF<1; 40% of coding genes) impact 406 
intelligence with small effect-size and are only mildly enriched in GOterms. This is reminiscent 407 
of GWAS results for schizophrenia showing that most GOterms contribute to it’s heritability 408 
[33]. 409 
 410 
Potential clinical application 411 
Models developed in this study provide a translation of gnomAD constraint scores into cognitive 412 
effect-sizes. Model outputs are implemented in a prediction tool (https://cnvprediction.urca.ca/), 413 
which is designed to estimate the population-average effect-size of any given CNV on general 414 
intelligence, not the cognitive ability of the individual who carries the CNV. If the cognitive 415 
deficits of an individual are concordant with the effect-size of the CNV they carry, one may 416 
conclude that the CNV contributes substantially to those deficits. When discordant (ie. The ob-417 
served IQ drop is ≥15 points (1SD) larger than the model estimate), the clinician may conclude 418 
that a substantial proportion of the contribution lies in additional factors which should be 419 
investigated, such as additional genetic variants and perinatal adverse events (e.g. neonatal 420 
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hypoxic ischemic injury, seizure disorders etc). If IQ cannot be reliably measured (ie. ≤ 4 years or 421 
in the case of severe behavioral disorders), the cognitive impact of the CNV predicted by the 422 
model may allow to anticipate the need for potential interventions. Overall, the output of this tool 423 
can help interpret CNVs in the clinic, but estimates should be interpreted with caution. The model 424 
can provide an estimate for the effect size on intelligence of individual genes when deleted. 425 
Therefore, one may use this information to estimate the effect size on intelligence of any SNV 426 
resulting in a loss of function. However, larger datasets are required to refine the estimates for 427 
individual gene. 428 
 429 
The relationship between genetic fitness and cognitive abilities 430 
The reasons underlying the tight relationship between general intelligence and epidemiological 431 
measures of intolerance to pLoF, is unclear. This relationship is further highlighted by the fact 432 
that deletions and duplications with the similar impact on intelligence occur de novo with similar 433 
frequencies. Behavioral interpretations are intuitive for severe ID but do not apply for CNVs with 434 
much milder effects. In other words, individuals with moderate or severe ID have limited 435 
offspring due to behavioral deficits but it is unclear how small changes in intelligence may lead 436 
to behavioral issues resulting in decreased fitness. Our results also suggest that genes considered 437 
as “tolerant” with LOEUF <1 affect cognitive abilities and are likely under “mild constraint”. 438 
Larger samples are required to better characterize the effect of this broad category of “mildly 439 
intolerant” genes on cognitive ability. 440 
 441 
Limitations 442 
The model relies on constraint scores (LOEUF or pLI), which are epidemiological measures of 443 
genetic fitness in human populations, without any consideration of gene function[18, 19]. It is 444 
likely that some genes decrease fitness (eg. genes involved in fertility) without affecting general 445 
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intelligence. Further studies combining intolerance scores with functional categories are required 446 
to investigate this question. While LOEUF was designed to measure intolerance to loss of 447 
function, we used it to assess both deletions and duplications. However, our results and a recent 448 
report suggest that it also measures the intolerance to increased gene expression [34]. Noise in 449 
the model may be related to unreliable constraint scores computed for small genes with a limited 450 
number of pLoF variants observed in the gnomAD database. Bias in the model may be 451 
introduced by ID genes observed in our dataset. Indeed, they may reflect a less severe subgroup 452 
and model outputs should be interpreted with caution when CNVs encompass ID-genes. Another 453 
potential bias is related to the fact that models were trained on CNVs encompassing 36% of the 454 
coding genome. Projections suggest that 500K individuals from an unselected population would 455 
cover 78% (Supplementary Fig. 12).  456 
Finally, all models imply additive effects and massive datasets would be required to test for gene-457 
gene and gene-environment interactions. However, the fact that very large CNVs (such as trisomy 458 
21) are accurately estimated by the model suggests that genetic interactions within large genomic 459 
segments or even chromosomes cannot be readily observed. There is long standing discordance 460 
between observations made at the microscopic and macroscopic level. Indeed, molecular studies 461 
provide unequivocal evidence that gene-gene interactions are common but quantitative genetic 462 
theory suggests that contributions from non-additive effects to phenotypic variation in the 463 
population are small. Reconciling these two observations, polygenic models assume that 464 
interactions are the rule rather than the exception. Interactions are, in fact, accounted for in the 465 
additive models[35]. For example, LOEUF values are correlated with the number of protein-466 
protein interactions[19] and our results also show that the intolerant genes are enriched in 467 
GOterms linked to “gene regulation”. In other words, the level of interactions for a given gene is 468 
directly related to its “individual” effect size on intelligence (ie. chromatin remodelers have a 469 




The effect-size of deletions or duplications on intelligence can be accurately estimated with 473 
additive models using constraint scores. The same relationship between gene dosage and 474 
cognition apply to small benign CNVs as well as extreme CNVs such as Down syndrome. We 475 
provide a map of effect-sizes at the individual gene level but to move beyond this rough outline, 476 
much larger sample sizes are required. Nonetheless, these results suggest that a large proportion 477 
(56%) of the coding genome covering all molecular functions influences cognitive abilities. One 478 
may therefore view the genetic contribution to cognitive difference as an emergent property of 479 
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22 12 (54%) 43 (21.27) WASI-II -0.04 (1.32) 
 646 
Table 1. Cohort descriptions 647 
Cohorts include 24,092 individuals, including 14,874 unrelated individuals. SSC and CaG 648 
cohorts were broken down into sub-samples based on array technology (Supplementary 649 
methods). †63 and ‡ 12 cognitive measures were respectively used to compute the g-factor in 650 
SYS children and parents (Supplementary methods). NDD: neurodevelopmental disorders, SYS: 651 
Saguenay Youth Study, CaG: CARTaGEN, LBC: Lothian Birth Cohort, SSC: Simons Simplex 652 
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Collection; n=number of individuals remaining for analysis after quality control. The mean and 653 
Standard Deviation (SD) for g-factor slightly deviate from 0 and 1 in some cohorts since they 654 
were computed on all available data (before the exclusion of some individuals for poor quality 655 
array) and summarized here only for individuals included in the analyses. *All individuals from 656 
LBC1936 were assessed at 70 years old explaining the absence of SD computation. **The NDD 657 
cohort was used only in the replication analysis and was not included in meta- or mega-analyses. 658 
*** We displayed the Z-scores of IQ, because IQ was preferred to g-factor for all analyses, even 659 
if results were similar (Supplementary Table 3 and 7). 660 
  661 
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Fig. 1. Effect of intolerant score on general intelligence measured for deletions and 662 
duplications.  663 
Meta-analysis estimating the effect of deletions a. and duplications b., measured by sum of pLI, 664 
on general intelligence (Supplementary Table 3). X-axis values represent z-scores of general 665 
intelligence. Deleting one point of pLI decreases the general intelligence by 0.18 z-scores (2.7 666 
points of IQ). Duplicating one point of pLI decreases the general intelligence by 0.05 z-scores 667 
(0.75 points of IQ). The squares represent the effect-size computed for each sample. Their size 668 
negatively correlated to variance. Diamonds represent the summary effect across cohorts. Their 669 
lengths correspond to the 95% confidence intervals of the mean effect-size. c. Estimated 670 
proportion of the coding genome within each category defined by LOEUF, encompassed in 671 
CNVs present in the mega-analysis according to sample size (randomly selected within the mega-672 
analysis). We observed NCNVs gene=6,315 with NDel. gene=2,282 and NDup. gene=5,223). d. Estimated 673 
effect of 1/LOEUF on general intelligence after removing individuals with a sum of 1/LOEUF 674 
larger than 60, 40, 20, 10, 4 and 2.85 (2.85 corresponds to 1/0.35, the cut-off for intolerance to 675 
pLoF gnomAD). n: number of individuals with a total sum of 1/LOEUF > 0. 676 
 677 
  678 
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Fig. 2. Effect-size of intellectual disability (ID) genes on general intelligence.  679 
a. Venn diagram of ID genes in ASD and in general population cohorts. We identified 66 CNVs 680 
encompassing at least one ID-gene in ASD cohorts (31 deletions and 35 duplications) and 60 in 681 
the general population (13 deletions and 47 duplications) (Supplementary methods). Genes were 682 
previously defined as harboring an excess of de novo loss of function (bold) or missense 683 
mutations in neurodevelopmental cohorts: (a) DYNC1H1, PHF21A, SHANK3, TRA2B, FOXP1, 684 
SETD5, NR4A2, TCF7L2, SOX5, POU3F3, ARID1B, EBF3, HNRNPU; (b) SET, ZBTB18, 685 
DLG4, CHAMP1, CNOT3, U2AF2, HIST1H2AC, DNM1, RAI1, CREBBP, HIST1H1E, 686 
ASXL1, CABP7; (c) PRPF18, PPP2R1A, EEF1A2; (d) TRAF7, DEAF1, STC1, MYT1L, BRPF1, 687 
CBL, SPAST, WDR87, NFE2L3, STARD9, TCF20, KMT2C, FAM200B, KDM5B, CHD2, 688 
BTF3, ITPR1, HMGXB3. b. Effect-size of 1/LOEUF on general intelligence estimated in a model 689 
using two explanatory variables (sum of 1/LOEUF of deleted and duplicated genes) or 4 690 
explanatory variables (sum of 1/LOEUF of ID genes and non-ID genes for deletions and 691 
duplication). 692 
 693 
  694 
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Fig. 3. Concordance between model predictions and published observations for CNV effects 695 
on general intelligence and for de novo frequency. 696 
a. and b. Concordance between model estimates (with 1/LOEUF and ID-genes) and literature of 697 
clinical data and UKBB reports for general intelligence loss observed in respectively 27 and 33 698 
recurrent CNVs for a total of ascertained carriers of 47 recurrent CNVs (Supplementary Table 699 
17). X- and Y-values: effect size of CNVs on z-scored general intelligence. b. Zoom of the 700 
rectangle drawn in the lower left section of panel a. We represented values from clinical data by a 701 
circle and those from UKBB data by a square. The cross represents the mean value of z-scored 702 
IQ loss for the 13 recurrent CNVs observed both in literature and in UKBB. c. and d. The model 703 
uses 2 explanatory variables (1/LOEUF of non-ID-genes and ID-genes). c. Probability of de novo 704 
estimated by our de novo model (Y-axis) according to the loss of IQ estimated by a model using 705 
1/LOEUF for ID and non-ID genes as two explanatory variables (X-axis). The de novo model 706 
was fitted on 13,114 deletions (red) and 13,323 duplications (blue) with available inheritance 707 
information observed in DECIPHER, CHU Sainte-Justine, SSC, MSSNG, SYS and G-Scot. d. 708 
Concordance between de novo frequency observed in DECIPHER (X-axis) and the probability of 709 
being de novo estimated by models when excluding recurrent CNVs of the training dataset (Y-710 
axis) 1/LOEUF for ID and non-ID genes as an explanatory variable for 27 recurrent CNVs. The 711 
first bisector represents the perfect concordance. Deletions are in red and duplications in blue. 712 
Empty circles or square are CNVs encompassing ID-genes. ICC indicates intraclass correlation 713 
coefficient (3, 1). Each point represents a recurrent CNV: (1) TAR Deletion; (2) 1q21.1 Deletion; 714 
(3) 2q11.2 Deletion; (4) 2q13 Deletion; (5) NRXN1 Deletion; (6) 2q13 (NPHP1) Deletion; (7) 715 
3q29 (DLG1) Deletion; (8) 7q11.23 (William-Beuren) Deletion; (9) 8p23.1 Deletion; (10) 716 
10q11.21q11.23 Deletion; (11) 13q12.12 Deletion; (12) 13q12 (CRYL1) Deletion; (13) 15q13.3 717 
(BP4-BP5) Deletion; (14) 15q11.2 Deletion; (15) 16p11.2-p12.2 Deletion; (16) 16p13.3 ATR-16 718 
syndrome Deletion; (17) 16p11.2 Deletion; (18) 16p11.2 distal Deletion; (19) 16p13.11 Deletion; 719 
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(20) 16p12.1 Deletion; (21) 17p11.2 (Smith-Magenis) Deletion; (22) 17q12 Deletion; (23) 720 
17q21.31 Deletion; (24) NF1-microdeletion syndrome Deletion; (25) 17p12 (HNPP) Deletion; 721 
(26) 22q11.2 Deletion; (27) TAR Duplication; (28) 1q21.1 Duplication; (29) 2q21.1 Duplication; 722 
(30) 2q13 Duplication; (31) 2q13 (NPHP1) Duplication; (32) 7q11.23 Duplication; (33) 723 
10q11.21q11.23 Duplication; (34) 13q12.12 Duplication; (35) 15q11q13 (BP3-BP4) Duplication; 724 
(36) 15q11.2 Duplication; (37) 15q13.3 Duplication; (38) 15q13.3 (CHRNA7) Duplication; (39) 725 
16p11.2 Duplication; (40) 16p11.2 distal Duplication; (41) 16p13.11 Duplication; (42) 16p12.1 726 
Duplication; (43) 17p11.2 Duplication; (44) 17q12 (HNF1B) Duplication; (45) 17p12 (CMT1A) 727 
Duplication; (46) Trisomic 21 Duplication; (47) 22q11.2 Duplication. 728 
  729 
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Fig. 4. Effect-size on general intelligence of individual genes encompassed in CNVs and 730 
their GOterms enrichment. 731 
a. , the light grey histogram represents the distribution of LOEUF values for 18,451 autosomal 732 
genes. The blue line represents the estimates for a gene in each of the 4 categories of LOEUF 733 
included in the model (Supplementary methods): highly intolerant genes (LOEUF <0.2, n=980), 734 
moderately intolerant genes (0.2≤LOEUF<0.35 n=1,762), tolerant genes (0.35≤LOEUF<1, 735 
n=7,442) and genes highly tolerant to pLoF (LOEUF≥1, n=8,267). The orange line represents the 736 
estimated effect-size of 37 categories of genes based on their LOEUF values (sliding 737 
windows=0.15) in the model (Supplementary methods). Genes with a LOEUF below 0.35 738 
(vertical red line) are considered to be intolerant to pLoF by gnomAD. Left Y-axis values: z-739 
scored general intelligence (1 z-score is equivalent to 15 points of IQ) for deletion. Right Y-axis 740 
values: number of genes represented in the histogram. b. each point represents a GOterm for 741 
which enrichment was observed for all intolerant (n=2,742) or tolerant genes (n=7,442), for all 742 
intolerant (n=609) or tolerant genes (n=2,251) encompassed in CNVs when compared to the 743 
whole coding genome (Bonferroni). X-axis: % of genes included in the GOterm genome-wide; 744 
Y-axis: % of genes included in the GOterm for all intolerant (0<LOEUF<0.35) and tolerant genes 745 
(0.35≤LOEUF<1). 746 
